Company · CIK 0001818794 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Dyne Therapeutics, Inc. · DYN
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 SForm 4 → | Sep 8, 4:13 pm EDT | John CoxCEO & President, Director | 5,658 | $18.88 | $106,823 | 357,507 | −1.56% | 10b5-1 |
| Sep 4, 2026 SForm 4 → | Sep 8, 4:15 pm EDT | Johanna Friedl-NadererChief Commercial Officer | 1,085 | $23.42 | $25,408 | 152,897 | −0.70% | 10b5-1 |
| Sep 4, 2026 SForm 4 → | Sep 8, 4:14 pm EDT | Douglas KerrChief Medical Officer | 5,035 | $22.95 | $115,546 | 162,564 | −3.00% | 10b5-1 |
| Aug 13, 2026 SForm 4 → | Aug 17, 5:30 pm EDT | Jason P RhodesDirector | 2,586,928 | $25.20 | $65,184,894 | 428,946 | −85.8% | 10b5-1 |
| Aug 13, 2026 SForm 4 → | Aug 17, 4:08 pm EDT | Johanna Friedl-NadererChief Commercial Officer | 226 | $26.28 | $5,939 | 153,982 | −0.15% | 10b5-1 |
| Aug 13, 2026 SForm 4 → | Aug 17, 4:08 pm EDT | Douglas KerrChief Medical Officer | 1,556 | $26.28 | $40,892 | 167,599 | −0.92% | 10b5-1 |
| Aug 13, 2026 SForm 4 → | Aug 17, 4:07 pm EDT | John CoxCEO & President, Director | 4,986 | $26.28 | $131,032 | 363,165 | −1.35% | 10b5-1 |
| Aug 13, 2026 SForm 4 → | Aug 17, 4:06 pm EDT | Erick LuceraChief Financial Officer | 1,797 | $26.28 | $47,225 | 119,766 | −1.48% | 10b5-1 |
| Jul 27, 2026 SForm 4 → | Jul 29, 4:15 pm EDT | Dirk KerstenDirector | 261,460 | $25.51 | $6,670,769 | 3,586,796 | −6.79% | 10b5-1 |
| Jul 6, 2026 SForm 4 → | Jul 8, 5:35 pm EDT | Jason P RhodesDirector | 777,451 | $22.97 | $17,858,492 | 2,962 | −99.6% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.